The selection of patients for PSMA radiopharmaceutical therapy is improved by a newly developed PSG score.

Published Date: 26 Apr 2023

The effectiveness of 177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) can be accurately predicted using a recently developed PSMA PET scoring system. international, multicenter testing.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Early detection of breast cancer may be possible with AI-based mammography microcalcification detection and classification.

4.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

5.

Efficacy and safety of intravenous chemotherapy in children with intraocular retinoblastoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot